{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T17:10:08Z","timestamp":1795108208448,"version":"4.10.3"},"reference-count":72,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>This review focuses on treatments for anti-MDA5 antibody-positive dermatomyositis (MDA5-DM), which is a subgroup of dermatomyositis and characterized by frequent rapidly progressive interstitial lung disease and the high mortality rate. Despite conventional immunosuppressive therapies, there are still refractory cases. Newer treatment options are needed.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>The triple combination therapy (high-dose glucocorticoids, calcineurin inhibitor, and intravenous cyclophosphamide) improved patient survival compared to high-dose glucocorticoids and step-wise addition of the immunosuppressants. The triple therapy now has been widely used, but there are still refractory cases. In addition to the conventional-type immunosuppressants, recently the efficacy of Janus kinase inhibitors, biologic agents such as rituximab, plasma exchange, and polymyxin B perfusion for refractory MDA5-DM patients have been reported. However, the majority of those reports regarding new treatments are limited to case series, retrospective studies, and small single-arm studies. Adding antifibrotic drugs to immunosuppressive therapies might have some ancillary benefits.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>Several new therapies for MDA5-DM patients have emerged, although the optimal use of those therapies is still unknown. Further research and evidence accumulation will be needed. It is also noted that the intensive immunosuppressive therapies are associated with the higher infection risk.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/bor.0000000000000979","type":"journal-article","created":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T14:00:59Z","timestamp":1694181659000},"page":"61-68","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":17,"title":["New therapies in anti-MDA5 antibody-positive dermatomyositis"],"prefix":"10.1097","volume":"36","author":[{"given":"Masahiro","family":"Yasui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taro","family":"Iwamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunsuke","family":"Furuta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,9,7]]},"reference":[{"key":"R1-20250526","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1186\/s40064-015-1013-8","article-title":"Incidence and impact of interstitial lung disease and malignancy in patients with polymyositis, dermatomyositis, and clinically amyopathic dermatomyositis: a retrospective cohort study","volume":"4","author":"Ikeda","year":"2015","journal-title":"Springerplus"},{"key":"R2-20250526","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1001\/jamaneurol.2018.2598","article-title":"Development of a new classification system for idiopathic inflammatory myopathies based on clinical manifestations and myositis-specific autoantibodies","volume":"75","author":"Mariampillai","year":"2018","journal-title":"JAMA Neurol"},{"key":"R3-20250526","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2147\/OARRR.S231195","article-title":"Myositis specific autoantibodies: a clinical perspective","volume":"12","author":"Alenzi","year":"2020","journal-title":"Open Access Rheumatol"},{"key":"R4-20250526","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1002\/acr.21992","article-title":"Anti-MDA5-associated dermatomyositis: expanding the clinical spectrum","volume":"65","author":"Hall","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R5-20250526","doi-asserted-by":"crossref","first-page":"319","DOI":"10.3899\/jrheum.160682","article-title":"Antimelanoma differentiation-associated gene 5 antibody: expanding the clinical spectrum in north American patients with dermatomyositis","volume":"44","author":"Moghadam-Kia","year":"2017","journal-title":"J Rheumatol"},{"key":"R6-20250526","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1177\/0961203316651748","article-title":"Clinical significance and new detection system of autoantibodies in myositis with interstitial lung disease","volume":"25","author":"Nakashima","year":"2016","journal-title":"Lupus"},{"key":"R7-20250526","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1093\/rheumatology\/key060","article-title":"Initial predictors of poor survival in myositis-associated interstitial lung disease: a multicentre cohort of 497 patients","volume":"57","author":"Sato","year":"2018","journal-title":"Rheumatology"},{"key":"R8-20250526","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s12016-015-8496-5","article-title":"Cutaneous manifestations in dermatomyositis: key clinical and serological features\u2014a comprehensive review","volume":"51","author":"Muro","year":"2016","journal-title":"Clin Rev Allergy Immunol"},{"key":"R9-20250526","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.jaad.2017.12.010","article-title":"Antimelanoma differentiation-associated gene 5 (MDA5) dermatomyositis: a concise review with an emphasis on distinctive clinical features","volume":"78","author":"Kurtzman","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"R10-20250526","first-page":"1719","article-title":"Combination therapy with corticosteroids, cyclosporin A, and intravenous pulse cyclophosphamide for acute\/subacute interstitial pneumonia in patients with dermatomyositis","volume":"32","author":"Kameda","year":"2005","journal-title":"J Rheumatol"},{"key":"R11-20250526","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/j.chest.2020.04.057","article-title":"Mortality risk prediction in amyopathic dermatomyositis associated with interstitial lung disease: the FLAIR model","volume":"158","author":"Lian","year":"2020","journal-title":"Chest"},{"key":"R12-20250526","doi-asserted-by":"crossref","first-page":"290797","DOI":"10.1155\/2014\/290797","article-title":"Anti-MDA5 antibodies in a large Mediterranean population of adults with dermatomyositis","volume":"2014","author":"Labrador-Horrillo","year":"2014","journal-title":"J Immunol Res"},{"key":"R13-20250526","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1002\/art.41105","article-title":"Multicenter prospective study of the efficacy and safety of combined immunosuppressive therapy with high-dose glucocorticoid, tacrolimus, and cyclophosphamide in interstitial lung diseases accompanied by antimelanoma differentiation-associated gene 5-positive dermatomyositis","volume":"72","author":"Tsuji","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"R14-20250526","doi-asserted-by":"crossref","first-page":"883699","DOI":"10.3389\/fmed.2022.883699","article-title":"Mortality risk stratification using cluster analysis in patients with myositis-associated interstitial lung disease receiving initial triple-combination therapy","volume":"9","author":"Gono","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"R15-20250526","doi-asserted-by":"crossref","first-page":"640","DOI":"10.3899\/jrheum.121043","article-title":"Mycophenolate mofetil improves lung function in connective tissue disease-associated interstitial lung disease","volume":"40","author":"Fischer","year":"2013","journal-title":"J Rheumatol"},{"key":"R16-20250526","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s10067-016-3443-2","article-title":"Mycophenolate mofetil for the patients with interstitial lung diseases in amyopathic dermatomyositis with anti-MDA-5 antibodies","volume":"36","author":"Hayashi","year":"2017","journal-title":"Clin Rheumatol"},{"key":"R17-20250526","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1080\/03009742.2017.1334814","article-title":"Describing and expanding the clinical phenotype of anti-MDA5-associated rapidly progressive interstitial lung disease: case series of nine Canadian patients and literature review","volume":"47","author":"Hoa","year":"2018","journal-title":"Scand J Rheumatol"},{"key":"R18-20250526","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1016\/j.rmed.2015.07.004","article-title":"Serum cytokine profiles of patients with interstitial lung disease associated with anti-CADM-140\/MDA5 antibody positive amyopathic dermatomyositis","volume":"109","author":"Takada","year":"2015","journal-title":"Respir Med"},{"key":"R19-20250526","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.annder.2013.04.083","article-title":"Dermatomyositis and acute interstitial lung disease associated with MDA-5 antibodies: an atypical case","volume":"140","author":"Girard","year":"2013","journal-title":"Ann Dermatol Venereol"},{"key":"R20-20250526","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1007\/s10067-015-2928-8","article-title":"Diagnosis and treatment of clinically amyopathic dermatomyositis (CADM): a case series and literature review","volume":"35","author":"Gil","year":"2016","journal-title":"Clin Rheumatol"},{"key":"R21-20250526","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s10067-015-3001-3","article-title":"Clinical and serological features of patients with dermatomyositis complicated by spontaneous pneumomediastinum","volume":"35","author":"Ma","year":"2016","journal-title":"Clin Rheumatol"},{"key":"R22-20250526","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s10067-012-2142-x","article-title":"Limitations of a single-point evaluation of anti-MDA5 antibody, ferritin, and IL-18 in predicting the prognosis of interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis","volume":"32","author":"Muro","year":"2013","journal-title":"Clin Rheumatol"},{"key":"R23-20250526","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1111\/bjd.16917","article-title":"Aberrant activation of the type I interferon system may contribute to the pathogenesis of antimelanoma differentiation-associated gene 5 dermatomyositis","volume":"180","author":"Zhang","year":"2019","journal-title":"Br J Dermatol"},{"key":"R24-20250526","first-page":"1","article-title":"Tofacitinib for new-onset adult patients with antimelanoma differentiation-associated 5 gene antibody positive dermatomyositis","volume":"3","author":"Wang","year":"2023","journal-title":"Clin Rheumatol"},{"key":"R25-20250526","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1093\/rheumatology\/kes102","article-title":"Anti-MDA5 antibody, ferritin and IL-18 are useful for the evaluation of response to treatment in interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis","volume":"51","author":"Gono","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"R26-20250526","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1016\/j.rmed.2015.07.004","article-title":"Serum cytokine profiles of patients with interstitial lung disease associated with anti-CADM-140\/MDA5 antibody positive amyopathic dermatomyositis","volume":"109","author":"Takada","year":"2015","journal-title":"Respir Med"},{"key":"R27-20250526","doi-asserted-by":"crossref","first-page":"633","DOI":"10.3109\/14397595.2013.844390","article-title":"Serum interleukin 6 levels as a useful prognostic predictor of clinically amyopathic dermatomyositis with rapidly progressive interstitial lung disease","volume":"24","author":"Nara","year":"2014","journal-title":"Mod Rheumatol"},{"key":"R28-20250526","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1093\/rheumatology\/key188","article-title":"Tofacitinib for refractory interstitial lung diseases in antimelanoma differentiation-associated 5 gene antibody-positive dermatomyositis","volume":"57","author":"Kurasawa","year":"2018","journal-title":"Rheumatology"},{"key":"R29-20250526","first-page":"291","article-title":"Intensive induction therapy combining tofacitinib, rituximab and plasma exchange in severe antimelanoma differentiation-associatedprotein-5 antibody-positive dermatomyositis","volume":"41","author":"Shirai","year":"2023","journal-title":"Clin Exp Rheumatol"},{"key":"R30-20250526","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1093\/mrcr\/rxac049","article-title":"Successful treatment with tofacitinib for relapse of rapidly progressive interstitial lung disease in antimelanoma differentiation-associated gene 5 antibody-positive clinically amyopathic dermatomyositis","volume":"7","author":"Hama","year":"2023","journal-title":"Mod Rheumatol Case Rep"},{"key":"R31-20250526","doi-asserted-by":"crossref","first-page":"e897","DOI":"10.1002\/iid3.897","article-title":"Case report: successful treatment of anti-MDA5-positive to negative dermatomyositis-associated interstitial lung disease with the JAK inhibitor tofacitinib","volume":"11","author":"Jiang","year":"2023","journal-title":"Immun Inflamm Dis"},{"key":"R32-20250526","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.jaad.2022.10.055","article-title":"JAK inhibitors for the treatment of adult dermatomyositis: A pilot study","volume":"88","author":"Landon-Cardinal","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"R33-20250526","article-title":"Successful peficitinib addition on anti-MDA5 antibody-positive dermatomyositis refractory to triple therapy and glucocorticoid reduction","volume":"10","author":"Oba","year":"2022","journal-title":"SAGE Open Med Case Rep"},{"key":"R34-20250526","doi-asserted-by":"crossref","first-page":"e221","DOI":"10.1093\/rheumatology\/keac084","article-title":"Good efficacy achieved by baricitinib in the treatment of anti-MDA5 antibody-positive dermatomyositis with alopecia areata","volume":"61","author":"Chen","year":"2022","journal-title":"Rheumatology"},{"key":"R35-20250526","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1093\/mrcr\/rxab054","article-title":"A case of clinically amyopathic dermatomyositis that was refractory to intensive immunosuppressive therapy including tofacitinib, but successfully treated with plasma exchange therapy","volume":"6","author":"Hiraoka","year":"2022","journal-title":"Mod Rheumatol Case Rep"},{"key":"R36-20250526","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.3390\/medicina57121358","article-title":"Combination therapy with rituximab, tofacitinib and pirfenidone in a patient with rapid progressive interstitial lung disease (RP-ILD) due to MDA5 antibody-associated dermatomyositis: a case report","volume":"57","author":"Yen","year":"2021","journal-title":"Medicina"},{"key":"R37-20250526","doi-asserted-by":"crossref","first-page":"S661","DOI":"10.1097\/RHU.0000000000001645","article-title":"A case of refractory interstitial lung disease in anti-MDA5-positive dermatomyositis that improved after switching to tofacitinib","volume":"27","author":"Hosokawa","year":"2021","journal-title":"J Clin Rheumatol"},{"key":"R38-20250526","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1016\/j.transproceed.2021.08.012","article-title":"High-emergency lung transplantation for interstitial lung disease associated with antimda5 dermatomyositis: a case report","volume":"53","author":"Marchiset","year":"2021","journal-title":"Transplant Proc"},{"key":"R39-20250526","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.revmed.2020.02.015","article-title":"Severe MDA5 dermatomyositis associated with cancer and controlled by JAK inhibitor","volume":"41","author":"Jalles","year":"2020","journal-title":"Rev Med Interne"},{"key":"R40-20250526","doi-asserted-by":"crossref","first-page":"e21943","DOI":"10.1097\/MD.0000000000021943","article-title":"Tofacitinib for recurrence of antimelanoma differentiation-associated gene 5 antibody-positive clinically amyopathic dermatomyositis after remission: a case report","volume":"99","author":"Ishikawa","year":"2020","journal-title":"Medicine"},{"key":"R41-20250526","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1007\/s00393-018-0565-8","article-title":"Response of dermatomyositis with lung involvement to Janus kinase inhibitor treatment","volume":"77","author":"Hornig","year":"2018","journal-title":"Z Rheumatol"},{"key":"R42-20250526","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1056\/NEJMc1900045","article-title":"Tofacitinib in amyopathic dermatomyositis-associated interstitial lung disease","volume":"381","author":"Chen","year":"2019","journal-title":"N Engl J Med"},{"key":"R43-20250526","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.3899\/jrheum.220367","article-title":"A retrospective analysis of outcome in melanoma differentiation-associated gene 5-related interstitial lung disease treated with tofacitinib or tacrolimus","volume":"49","author":"Fan","year":"2022","journal-title":"J Rheumatol"},{"key":"R44-20250526","first-page":"70","article-title":"Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis","volume":"13","author":"Balzola","year":"2012","journal-title":"Inflamm Bowel Dis Monitor"},{"key":"R45-20250526","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1080\/24725625.2020.1816674","article-title":"Successful dose escalation of tofacitinib for refractory dermatomyositis and interstitial lung disease with antimelanoma differentiation-associated gene 5 antibodies","volume":"5","author":"Ohmura","year":"2021","journal-title":"Mod Rheumatol Case Rep"},{"key":"R46-20250526","doi-asserted-by":"crossref","first-page":"e002795","DOI":"10.1136\/rmdopen-2022-002795","article-title":"Clinical case: efficacy and safety of dose escalation of tofacitinib in refractory anti-MDA5 antibody-positive dermatomyositis","volume":"9","author":"Ida","year":"2023","journal-title":"RMD Open"},{"key":"R47-20250526","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/bjd.14882","article-title":"Antimelanoma differentiation-associated protein 5 antibody level is a novel tool for monitoring disease activity in rapidly progressive interstitial lung disease with dermatomyositis","volume":"176","author":"Matsushita","year":"2017","journal-title":"Br J Dermatol"},{"key":"R48-20250526","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1007\/s10067-018-4122-2","article-title":"Rituximab for refractory rapidly progressive interstitial lung disease related to anti-MDA5 antibody-positive amyopathic dermatomyositis","volume":"37","author":"So","year":"2018","journal-title":"Clin Rheumatol"},{"key":"R49-20250526","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1007\/s10067-020-05530-5","article-title":"Antimelanoma differentiation-associated gene 5 (MDA5) antibody-positive dermatomyositis responds to rituximab therapy","volume":"40","author":"Ge","year":"2021","journal-title":"Clin Rheumatol"},{"key":"R50-20250526","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1136\/annrheumdis-2014-205278","article-title":"Basiliximab may improve the survival rate of rapidly progressive interstitial pneumonia in patients with clinically amyopathic dermatomyositis with anti-MDA5 antibody","volume":"73","author":"Zou","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"R51-20250526","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1007\/s00296-022-05176-3","article-title":"New-onset dermatomyositis following SARS-CoV-2 infection and vaccination: a case-based review","volume":"42","author":"Holzer","year":"2022","journal-title":"Rheumatol Int"},{"key":"R52-20250526","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1080\/03009742.2021.1972519","article-title":"Tocilizumab and rituximab for anti-MDA-5 positive amyopathic dermatomyositis complicated with macrophage activation syndrome and progressive fibrosing interstitial lung disease","volume":"51","author":"Su","year":"2022","journal-title":"Scand J Rheumatol"},{"key":"R53-20250526","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1007\/s00296-012-2653-4","article-title":"Efficacy of infliximab in the treatment for dermatomyositis with acute interstitial pneumonia: a study of fourteen cases and literature review","volume":"33","author":"Chen","year":"2013","journal-title":"Rheumatol Int"},{"key":"R54-20250526","article-title":"Pirfenidone in patients with rapidly progressive interstitial lung disease associated with clinically amyopathic dermatomyositis OPEN","author":"Li","year":"2016","journal-title":"Nature Publishing Group"},{"key":"R55-20250526","doi-asserted-by":"crossref","first-page":"626953","DOI":"10.3389\/fmed.2021.626953","article-title":"Efficacy and tolerability of nintedanib in idiopathic-inflammatory-myopathy-related interstitial lung disease: a pilot study","volume":"8","author":"Liang","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"R56-20250526","doi-asserted-by":"crossref","first-page":"496","DOI":"10.3109\/s10165-012-0663-4","article-title":"Anticadm-140\/mda5 autoantibody titer correlates with disease activity and predicts disease outcome in patients with dermatomyositis and rapidly progressive interstitial lung disease","volume":"23","author":"Sato","year":"2013","journal-title":"Mod Rheumatol"},{"key":"R57-20250526","doi-asserted-by":"crossref","first-page":"102941","DOI":"10.1016\/j.jaut.2022.102941","article-title":"Efficacy of plasma exchange in patients with anti-MDA5 rapidly progressive interstitial lung disease","volume":"133","author":"Bay","year":"2022","journal-title":"J Autoimmun"},{"key":"R58-20250526","doi-asserted-by":"crossref","first-page":"3284","DOI":"10.1093\/rheumatology\/keaa123","article-title":"Efficacy of plasma exchange in anti-MDA5-positive dermatomyositis with interstitial lung disease under combined immunosuppressive treatment","volume":"59","author":"Shirakashi","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"R59-20250526","first-page":"1410","article-title":"Early initiation of plasma exchange therapy for anti-MDA5+ dermatomyositis with refractory rapidly progressive interstitial lung disease","author":"Sasaki","year":"2023","journal-title":"Intern Med"},{"key":"R60-20250526","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.transci.2006.06.006","article-title":"Endotoxin apheresis for sepsis","volume":"35","author":"Shimizu","year":"2006","journal-title":"Transfus Apher Sci"},{"key":"R61-20250526","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ijms22042228","article-title":"Therapeutic rationale for endotoxin removal with polymyxin B immobilized fiber column (PMX) for septic shock","volume":"22","author":"Shoji","year":"2021","journal-title":"Int J Mol Sci"},{"key":"R62-20250526","doi-asserted-by":"crossref","first-page":"R653","DOI":"10.1186\/cc3815","article-title":"Early hemoperfusion with an immobilized polymyxin B fiber column eliminates humoral mediators and improves pulmonary oxygenation","volume":"9","author":"Kushi","year":"2005","journal-title":"Crit Care"},{"key":"R63-20250526","first-page":"51","article-title":"Rapidly progressive interstitial lung disease due to anti-MDA-5 antibody-positive clinically amyopathic dermatomyositis complicated with cervical cancer: Successful treatment with direct hemoperfusion using polymyxin B-immobilized fiber column therapy","volume":"20","author":"Ichiyasu","year":"2017","journal-title":"Respir Med Case Rep"},{"key":"R64-20250526","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1002\/jca.21833","article-title":"Anti-MDA-5 antibody-positive clinically amyopathic dermatomyositis with rapidly progressive interstitial lung disease treated with therapeutic plasma exchange: a case series","volume":"36","author":"Saito","year":"2021","journal-title":"J Clin Apher"},{"key":"R65-20250526","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1378\/chest.13-0186","article-title":"Successful polymyxin B hemoperfusion treatment associated with serial reduction of serum anti-CADM-140\/MDA5 antibody levels in rapidly progressive interstitial lung disease with amyopathic dermatomyositis","volume":"144","author":"Teruya","year":"2013","journal-title":"Chest"},{"key":"R66-20250526","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s12890-017-0479-2","article-title":"Clinical effects of direct hemoperfusion using a polymyxin B-immobilized fiber column in clinically amyopathic dermatomyositis-associated rapidly progressive interstitial pneumonias","volume":"17","author":"Okabayashi","year":"2017","journal-title":"BMC Pulm Med"},{"key":"R67-20250526","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1007\/s10067-022-06422-6","article-title":"Lung transplantation for anti-MDA5-positive dermatomyositis-associated rapid progressive interstitial lung disease: report of two cases and review of the literature","volume":"42","author":"Lian Q.","year":"2023","journal-title":"Clin Rheumatol"},{"key":"R68-20250526","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1007\/s11748-012-0106-3","article-title":"Living-donor lobar lung transplantation for rapidly progressive interstitial pneumonia associated with clinically amyopathic dermatomyositis: report of a case","volume":"61","author":"Shoji","year":"2013","journal-title":"Gen Thorac Cardiovasc Surg"},{"key":"R69-20250526","doi-asserted-by":"crossref","first-page":"581","DOI":"10.3899\/jrheum.171047","article-title":"Successful lung transplantation in a case of rapidly progressive interstitial lung disease associated with antimelanoma differentiation-associated gene 5 antibodies","volume":"45","author":"Leclair","year":"2018","journal-title":"J Rheumatol"},{"key":"R70-20250526","first-page":"28","article-title":"Rapidly progressive interstitial lung disease due to antimelanoma differentiation associated protein-5 requiring a bilateral lung transplant, and complicated by kennel cough","author":"Deitchman","year":"2019","journal-title":"Respir Med Case Rep"},{"key":"R71-20250526","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1093\/rheumatology\/keaa032","article-title":"Successful lung transplant in rapid progressive interstitial lung disease associated with antimelanoma differentiation associated gene 5","volume":"59","author":"Huang","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"R72-20250526","first-page":"6097183","article-title":"Spontaneous pneumomediastinum due to antimelanoma differentiation-associated protein 5 requiring a bilateral lung transplant","volume":"2021","author":"Jhajj","year":"2021","journal-title":"Case Rep Rheumatol"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000000979","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T21:20:46Z","timestamp":1748294446000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000000979"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,7]]},"references-count":72,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0000000000000979","relation":{},"ISSN":["1040-8711","1531-6963"],"issn-type":[{"value":"1040-8711","type":"print"},{"value":"1531-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,7]]}}}